The Next Frontier in Inhaled Drug Development: Bridging Decades of Expertise with Emerging Technologies

Kate GreenUncategorized

A conversation with Ted Barrett of Lovelace Biomedical and Per Gerde of Inhalation Sciences

Inhaled drug development has come a long way from its early roots in environmental exposure and respiratory toxicology research. Today, increasingly complex therapies, including biologics, nucleic acid-based treatments and advanced formulations, are creating new opportunities to deliver medicines directly to the lungs and through the nasal passages. But they are also introducing challenges that traditional development approaches were not designed to address.

For researchers, the need for precise dosing, predictive preclinical models and better translation between early laboratory studies and later-stage development has never been greater.

Few organizations have witnessed this evolution as closely as Lovelace Biomedical, whose history in inhalation research spans nearly 60 years. That history also connects to Inhalation Sciences, whose technology has roots in research conducted at Lovelace in the 1990s. Today, the two organizations are collaborating to explore new approaches for improving the preclinical development process by combining established scientific expertise with emerging technologies.

We spoke with Ted Barrett of Lovelace Biomedical and Per Gerde of Inhalation Sciences about how the field has evolved, where the greatest challenges and opportunities lie, and how bringing their complementary capabilities together could help advance the next generation of inhaled therapies.

Q: How has inhalation research evolved over the past several decades, and what does that history tell us about where the industry is headed?

Ted Barrett: Lovelace’s history in inhalation research goes back nearly 60 years, when much of the focus was on understanding the health effects of environmental exposures, including airborne pollutants, cigarette smoke and inhaled radionuclides. We developed sophisticated methods to study how inhaled substances behave in the body and what effects they produce.


As the pharmaceutical industry began exploring the lungs as a route for drug delivery, many of those same principles and techniques became directly applicable. The fundamental science of aerosol delivery, deposition and distribution hasn’t changed. What has changed is what we’re trying to accomplish. We’ve leveraged our understanding of the potential harm of inhaled substances to intentionally delivering therapies that can benefit patients.

Per Gerde: I experienced that evolution firsthand. I began working at Lovelace in the 1990s, when environmental and air pollution research dominated much of the work. What impressed me was the multidisciplinary approach. Researchers from different scientific backgrounds worked together to solve complex problems, which wasn’t always common in academic
environments at the time.


Much of the foundational aerosol science developed during those years remains relevant today. In some cases, researchers are revisiting questions that were studied decades ago, but now with entirely new therapeutic applications.


Q: What are the biggest challenges facing developers of inhaled therapies today?


Per Gerde: The complexity of the therapies themselves has changed dramatically. We’re seeing more biologics, sophisticated formulations and products containing multiple active pharmaceutical ingredients. These advances create opportunities, but they also introduce significant technical challenges.

One of the biggest is the cost of the materials being studied. Some of these compounds are extremely expensive, so researchers need ways to generate meaningful data using very small quantities of a test substance. That makes efficient, precise early-stage testing increasingly important.

Ted Barrett: Nucleotide-based therapies are a good example. Beyond the cost of the material, there are questions about how to deliver these molecules without damaging them, how they distribute within the respiratory system, whether they reach their intended cellular targets and how we measure their activity.

We’re also seeing challenges with nasal delivery, particularly dry powder formulations. Delivering a consistent, well-characterized dose to the nasal passages in preclinical models is not straightforward. These are areas where better technologies and methods are needed.

Q: How can emerging technologies help address these challenges and improve early development decisions?

Per Gerde: One important opportunity is improving the consistency of aerosol delivery across different experimental models.


Inhalation Science’s PreciseInhale technology grew out of work that began at Lovelace. It was developed to generate and precisely deliver aerosols to different testing systems while minimizing the amount of material required.

The system can accommodate different aerosol sources, including dry powder and liquid formulations from a range of devices, and deliver them to a range of models, from cell cultures and isolated lungs to in vivo studies.

The advantage is that researchers can evaluate different formulations and move between experimental models without introducing unnecessary variability through changes in the exposure method. That can help improve the quality of early data and reduce uncertainty as development progresses.

Ted Barrett: There’s also an opportunity to incorporate emerging delivery technologies. For example, newer microfluidic and soft mist approaches may offer gentler delivery for delicate formulations such as lipid nanoparticles.

The important thing is understanding how these technologies perform and how they can be integrated into established preclinical models. It’s not simply about generating an aerosol. It’s about knowing what is delivered, where it goes and what happens afterward.

Q: There’s increasing emphasis on more predictive preclinical models and reducing animal testing. How do you see that changing inhaled drug development?

Per Gerde: Better in vitro and ex vivo models can provide valuable information before moving into more complex animal studies. For example, we can study dissolution, absorption and cellular uptake/exposure using controlled aerosol delivery systems.

These approaches align with the principles of replacing, reducing and refining animal research, commonly known as the 3Rs. More precise dosing and earlier understanding of dose kinetics-translation may help improve in vivo study designs.

In vivo studies still have an essential role. The objective should be to use the most appropriate model at each stage and ensure that the information generated is as useful as possible.

Ted Barrett: I agree. It’s about applying the right tools in the right context to the right scientific questions. Combining newer exposure technologies with established biological models gives researchers more options for understanding how these increasingly complex therapies behave.

Q: What makes the collaboration between Lovelace Biomedical and Inhalation Sciences particularly relevant now?

Ted Barrett: In many ways, we’re taking established scientific capabilities and finding new applications for them.

Lovelace has decades of experience in inhalation toxicology, pharmacology and preclinical research, including exposure systems and models that were originally developed for different scientific questions.

Inhalation Sciences brings an enhanced approach to aerosol generation and delivery that can give some of those established models renewed utility, particularly for newer biologics and nucleotide-based therapies.

Together, there’s an opportunity to connect precise early exposure studies with more comprehensive evaluations of dose translation, efficacy, and safety.

Per Gerde: There’s also a personal connection. Some of the concepts behind our technology originated during my time at Lovelace, so bringing these capabilities together feels like a natural progression.

Lovelace has access to a broad range of exposure systems and biological models, while our technology is focused on precise aerosol delivery and early characterization. Integrating those capabilities could help researchers move between different experimental systems with fewer inconsistencies in dosing.

The collaboration also brings together complementary experience and capabilities in Europe and the United States.

Q: Looking ahead five to ten years, where do you see the greatest opportunities for inhaled drug development?

Ted Barrett: I expect we’ll see continued growth in nasal delivery, including nose-to-brain applications, vaccines and therapies designed for rapid systemic delivery. As our understanding of nasal deposition and absorption improves, it could open new possibilities for more patient-friendly treatments.

I also think we’ll see greater interest in delivering biologics to the lungs, potentially for increasingly targeted, disease/patient-specific applications.

Per Gerde: As therapies become more sophisticated, the ability to generate consistent, meaningful data across different models will become even more important.

We need to reduce the uncertainty that can arise when moving from cell cultures to animal models to human trials. Better integration of exposure technologies and biological models can help address that challenge.

Ultimately, progress won’t come from any single technology. It will come from combining scientific expertise, better experimental methods and closer collaboration across disciplines.

Ted Barrett: That’s really the opportunity. The industry has an extraordinary foundation of scientific knowledge. The challenge now is applying it in new ways to address the increasingly complex therapies being developed today.